Can a Patient with Ulcerative Colitis Use Zepbound?
Yes, a patient with ulcerative colitis can use Zepbound (tirzepatide), as there is no evidence of contraindication or interaction between this GLP-1/GIP receptor agonist weight loss medication and ulcerative colitis or its treatments.
Key Considerations
No Direct Contraindication
- Zepbound (tirzepatide) is a GLP-1/GIP receptor agonist approved for chronic weight management and does not have any known mechanism that would worsen inflammatory bowel disease or interfere with ulcerative colitis pathophysiology.
- The AGA guidelines for ulcerative colitis management 1, 2 do not list GLP-1 receptor agonists as contraindicated medications in patients with UC.
Practical Clinical Concerns
Gastrointestinal Side Effects:
- The primary concern is that Zepbound commonly causes gastrointestinal side effects including nausea, diarrhea, and abdominal discomfort, which could potentially be confused with UC flare symptoms.
- In a patient with active or moderately severe UC, these overlapping symptoms could complicate disease monitoring and assessment of UC disease activity 3.
Timing Considerations:
- Ideal scenario: Start Zepbound when the patient's UC is in stable remission on appropriate therapy (infliximab, vedolizumab, ustekinumab, JAK inhibitors, or S1P modulators) 1, 2.
- Avoid initiation: During active UC flares or when disease activity is being assessed, as the medication's GI side effects will confound symptom evaluation.
Monitoring Strategy
If prescribing Zepbound to a UC patient:
- Ensure UC is in documented remission with objective markers (fecal calprotectin, endoscopic assessment) before starting 3.
- Educate the patient to distinguish between expected Zepbound GI side effects (typically improve over weeks) versus UC symptoms (bloody diarrhea, urgency, nocturnal symptoms).
- Consider more frequent monitoring of inflammatory biomarkers (fecal calprotectin) during Zepbound titration to ensure UC remains controlled.
- Maintain the patient's UC maintenance therapy without interruption 1, 2.
No Drug-Drug Interactions
- Zepbound does not interact with advanced UC therapies including TNF antagonists (infliximab, adalimumab, golimumab), vedolizumab, ustekinumab, JAK inhibitors (tofacitinib, upadacitinib, filgotinib), or S1P modulators (ozanimod, etrasimod) 1, 2, 4.
Clinical Algorithm
- Assess UC disease activity - Patient must be in clinical and biochemical remission
- Confirm stable maintenance therapy - Patient on appropriate advanced therapy per AGA guidelines 2
- Counsel patient - Explain potential for overlapping GI symptoms
- Initiate Zepbound - Standard dosing and titration
- Monitor closely - Use objective biomarkers (fecal calprotectin) rather than symptoms alone during first 3 months
- Maintain UC therapy - Continue all UC medications without modification
The decision to use Zepbound should prioritize maintaining UC remission, as uncontrolled UC significantly impacts morbidity and quality of life more than the benefits of weight loss medication.